Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT

Fig. 1

A–D Day-100 landmark analyses (n = 477) showing the impact of grade I, II and grade III–IV acute GVHD on: A relapse incidence (P = 0.39); B incidence of nonrelapse mortality (NRM, P = 0.001); C Leukemia-free survival (LFS, P = 0.005); D overall survival (OS, P = 0.002). E–H Day-365 landmark analyses (n = 234) showing the impact of limited and extensive chronic GVHD on: E relapse incidence (P = 0.8); F NRM (P = 0.021); G LFS (P = 0.11); H OS (P = 0.014)

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us